ALK inhibitors and checkpoint blockade: a cautionary tale of mixing oil with water?
作者信息
Patel Malini, Jabbour Salma K, Malhotra Jyoti
机构信息
Rutgers Cancer Institute of New Jersey and Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
出版信息
J Thorac Dis. 2018 Jul;10(Suppl 18):S2198-S2201. doi: 10.21037/jtd.2018.06.118.
Abstract
摘要
相似文献
1
ALK inhibitors and checkpoint blockade: a cautionary tale of mixing oil with water?间变性淋巴瘤激酶（ALK）抑制剂与免疫检查点阻断：将油与水混合的警示故事？
J Thorac Dis. 2018 Jul;10(Suppl 18):S2198-S2201. doi: 10.21037/jtd.2018.06.118.
2
"A cautionary tale...after oil spills". Reply by Dr. Robert J. Lawrence.“一个警示故事……石油泄漏之后”。罗伯特·J·劳伦斯博士的回复。
Mar Pollut Bull. 2008 Jul;56(7):1381. doi: 10.1016/j.marpolbul.2008.06.006.
3
A cautionary tale about evaluating analytical methods to assess contamination after oil spills.一个关于评估分析方法以评估石油泄漏后污染情况的警示故事。
Mar Pollut Bull. 2008 Jul;56(7):1380. doi: 10.1016/j.marpolbul.2008.03.024. Epub 2008 Apr 29.
4
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
5
A cautionary TALE: how plant breeding may have favoured expanded TALE repertoires in Xanthomonas.一则警示故事：植物育种如何可能促进了黄单胞菌中TALE序列的扩增
Mol Plant Pathol. 2018 Jun;19(6):1297-1301. doi: 10.1111/mpp.12670.
6
Proton-pump inhibitor overuse: a cautionary tale in misguided benefit.质子泵抑制剂的过度使用：一个关于错误认知益处的警示故事。
Intern Med J. 2019 Oct;49(10):1337. doi: 10.1111/imj.14452.
7
Characterization of oil and water accommodated fractions used to conduct aquatic toxicity testing in support of the Deepwater Horizon oil spill natural resource damage assessment.用于开展水生毒性测试以支持深水地平线漏油事件自然资源损害评估的油相和水相可容纳组分的特性分析。
Environ Toxicol Chem. 2017 Jun;36(6):1450-1459. doi: 10.1002/etc.3672. Epub 2016 Dec 9.
8
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.癌症的免疫检查点阻断疗法：FDA 批准的免疫检查点抑制剂概述。
Int Immunopharmacol. 2018 Sep;62:29-39. doi: 10.1016/j.intimp.2018.06.001. Epub 2018 Jul 2.
9
ALK Inhibitors-Induced M Phase Delay Contributes to the Suppression of Cell Proliferation.间变性淋巴瘤激酶（ALK）抑制剂诱导的M期延迟有助于抑制细胞增殖。
Cancers (Basel). 2020 Apr 24;12(4):1054. doi: 10.3390/cancers12041054.
10
Hot water bottles and diabetic patients--a cautionary tale.热水袋与糖尿病患者——一则警示故事。
Br J Gen Pract. 2005 Mar;55(512):222-3.
引用本文的文献
1
Mechanisms of Resistance to ALK Inhibitors and Corresponding Treatment Strategies in Lung Cancer.肺癌中对ALK抑制剂的耐药机制及相应治疗策略
Int J Gen Med. 2025 Apr 15;18:2151-2171. doi: 10.2147/IJGM.S512395. eCollection 2025.
2
ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies.癌症中的ALK抑制剂：耐药机制与治疗管理策略
Cancer Drug Resist. 2024 May 23;7:20. doi: 10.20517/cdr.2024.25. eCollection 2024.
3
Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions.揭示ALK靶向治疗在非小细胞肺癌中的潜力：全面见解与未来方向
Biomedicines. 2024 Jan 27;12(2):297. doi: 10.3390/biomedicines12020297.
4
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.MRTX-500 二期临床试验：Sitravatinib 联合纳武利尤单抗治疗接受过免疫检查点抑制剂治疗或化疗后进展的非鳞状非小细胞肺癌患者。
J Thorac Oncol. 2023 Jul;18(7):907-921. doi: 10.1016/j.jtho.2023.02.016. Epub 2023 Feb 24.
5
ALK-positive lung cancer: a moving target.ALK 阳性肺癌：一个移动的目标。
Nat Cancer. 2023 Mar;4(3):330-343. doi: 10.1038/s43018-023-00515-0. Epub 2023 Feb 16.
6
Anti-Angiogenic Therapy in Rearranged Non-Small Cell Lung Cancer (NSCLC).抗血管生成治疗在非小细胞肺癌（NSCLC）中的应用。
Int J Mol Sci. 2022 Aug 9;23(16):8863. doi: 10.3390/ijms23168863.
7
Anaplastic lymphoma kinase-special immunity and immunotherapy.间变性淋巴瘤激酶-特异性免疫与免疫治疗。
Front Immunol. 2022 Jul 25;13:908894. doi: 10.3389/fimmu.2022.908894. eCollection 2022.
8
Immunotherapy in oncogene addicted non-small cell lung cancer.针对癌基因成瘾性非小细胞肺癌的免疫疗法。
Transl Lung Cancer Res. 2021 Jun;10(6):2736-2751. doi: 10.21037/tlcr-20-772.
9
Therapeutic Sequencing in ALK NSCLC.ALK 非小细胞肺癌的治疗顺序
Pharmaceuticals (Basel). 2021 Jan 21;14(2):80. doi: 10.3390/ph14020080.
10
The future of cancer immunotherapy: microenvironment-targeting combinations.癌症免疫疗法的未来：靶向微环境的联合疗法。
Cell Res. 2020 Jun;30(6):507-519. doi: 10.1038/s41422-020-0337-2. Epub 2020 May 28.
本文引用的文献
1
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.纳武利尤单抗治疗经治晚期非小细胞肺癌的 5 年随访结果：CA209-003 研究结果。
J Clin Oncol. 2018 Jun 10;36(17):1675-1684. doi: 10.1200/JCO.2017.77.0412. Epub 2018 Mar 23.
2
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.度伐利尤单抗作为晚期非小细胞肺癌的三线或后线治疗药物（ATLANTIC）：一项开放标签、单臂、2 期研究。
Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.
3
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).纳武利尤单抗联合克唑替尼用于治疗间变性淋巴瘤激酶融合阳性的晚期非小细胞肺癌（CheckMate 370）的一线治疗的安全性和耐受性的 1/2 期研究。
J Thorac Oncol. 2018 May;13(5):682-688. doi: 10.1016/j.jtho.2018.02.022. Epub 2018 Mar 6.
4
Current state of immunotherapy for non-small cell lung cancer.非小细胞肺癌免疫治疗的现状
Transl Lung Cancer Res. 2017 Apr;6(2):196-211. doi: 10.21037/tlcr.2017.03.01.
5
Crizotinib resistance: implications for therapeutic strategies.克唑替尼耐药性：对治疗策略的影响。
Ann Oncol. 2016 Sep;27 Suppl 3(Suppl 3):iii42-iii50. doi: 10.1093/annonc/mdw305.
6
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.表皮生长因子受体（EGFR）突变和间变性淋巴瘤激酶（ALK）重排与非小细胞肺癌中PD-1通路阻断的低反应率相关：一项回顾性分析
Clin Cancer Res. 2016 Sep 15;22(18):4585-93. doi: 10.1158/1078-0432.CCR-15-3101. Epub 2016 May 25.
7
Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients.EML4-ALK融合蛋白上调PD-L1介导ALK阳性非小细胞肺癌的免疫逃逸：对ALK-TKIs敏感和耐药的非小细胞肺癌患者选择抗PD-1/PD-L1免疫治疗的启示
Oncoimmunology. 2015 Dec 21;5(3):e1094598. doi: 10.1080/2162402X.2015.1094598. eCollection 2016 Mar.
8
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.克唑替尼对比化疗用于治疗 ALK 阳性肺癌。
N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440.
9
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.克唑替尼与化疗用于治疗晚期 ALK 阳性肺癌。
N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1.
10
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.非小细胞肺癌中转化型EML4-ALK融合基因的鉴定。
Nature. 2007 Aug 2;448(7153):561-6. doi: 10.1038/nature05945. Epub 2007 Jul 11.
Zotero 插件